CellBio technology

 

Category: Precision Medicine

Exhibitor: GENERAL BIOLOGICALS CORPORATION (GBC)

Booth No: S610

 

Characteristic

 

The GBC (General Biologicals Corporation), as a pioneer and manufacturer in the diagnostics and pharmaceutical industry, has innovated and developed The CellBio technology performed as a game-changer for isolating circulating tumor cells (CTC) from blood and subsequently uses fluorescent staining for cell characterization by fluorescence microscopy. CellBio technology, including instruments and kits, has been optimized for enumeration and phenotypic classification of circulating tumor cells (CTC) for clinical decision-making. According to the latest research, the relevance of CTC for tumor diagnosis, prognosis or monitoring of recurrence after treatment is increasing, so the recovery rate and purity of CTC isolation are crucial for accurate prediction of tumor progression. At present, a variety of methods have been developed on the market for CTC isolation. The CellBio technology can simultaneously use the microfilter and fluorescent staining to separate and recover CTCs from human blood samples according to the size of cells and different surface markers. The CellBio technology at GBC has demonstrated the CTC recovery efficiency of>90 % with in-vitro samples which is better than available market techniques. The optimized structure and process design of the filter membrane are designed to separate CTCs from other blood cells while avoiding cell damage or deformation during filtration. The characterization process is developed for recognizing frequently overexpressed EPCAM and cytokeratin receptors on circulating tumor cells. During characterization, the non-nucleated interference was neglected by DAPI staining and leukocytes by CD45 recognition. The CellBiotechnology is not only offering high sensitivity and specificity enabling the researchers to analyze CTC but also provides an effective tool for understanding tumor progression.

 

 

 

Back